Cancer cells with deficient HR are exquisitely sensitive to inhibition of PARP [12, 13] and several PARPis are now approved for the treatment of BRCA1/2-mutated ovarian and breast cancers, with dozens more in various stages of preclinical and clinical development [15, 16]. Here, PARP1 is linked to breast carcinoma.